The average P/S ratio for APLS's competitors is 29.10, providing a benchmark for relative valuation. Apellis Pharmaceuticals Inc Corp (APLS) exhibits a P/S ratio of 2.70, which is -90.73% above the industry average. Given its robust revenue growth of -3.21%, this premium appears unsustainable.